scholarly journals Effects of a Brazilian cardioprotective diet and nuts on cardiometabolic parameters after myocardial infarction: study protocol for a randomized controlled clinical trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Aline Marcadenti ◽  
Bernardete Weber ◽  
Angela Cristine Bersch-Ferreira ◽  
Rachel Helena Vieira Machado ◽  
Camila Ragne Torreglosa ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Clinical Trial ◽  
Cardiovascular Prevention ◽  
World Health ◽  
Controlled Clinical Trial ◽  
Beneficial Effects ◽  
Brazil Nuts ◽  
Glycemic Profile ◽  
Group 2 ◽  
Health Organization

Abstract Background Nut consumption has been related to improvements on cardiometabolic parameters and reduction in the severity of atherosclerosis mainly in primary cardiovascular prevention. The objective of this trial is to evaluate the effects of the Brazilian Cardioprotective Diet (DIetaCArdioprotetoraBrasileira, DICA Br) based on consumption of inexpensive locally accessible foods supplemented or not with mixed nuts on cardiometabolic features in patients with previous myocardial infarction (MI). Methods DICA-NUTS study is a national, multicenter, randomized 16-week follow-up clinical trial. Patients over 40 years old with diagnosis of previous MI in the last 2 to 6 months will be recruited (n = 388). A standardized questionnaire will be applied to data collection and blood samples will be obtained. Patients will be allocated in two groups: Group 1: DICA Br supplemented with 30 g/day of mixed nuts (10 g of peanuts, 10 g of cashew, 10 g of Brazil nuts); and Group 2: only DICA Br. The primary outcome will consist of LDL cholesterol means (in mg/dL) after 16 weeks of intervention. Secondary outcomes will consist of other markers of lipid profile, glycemic profile, and anthropometric data. Discussion It is expected that DICA Br supplemented with mixed nuts have superior beneficial effects on cardiometabolic parameters in patients after a MI, when compared to DICA Br. Trial registration ClinicalTrials.gov Identifier NCT03728127. First register: November 1, 2018; Last update: June 16, 2021. World Health Organization Universal Trial Number (WHO-UTN): U1111-1259-8105.

scholarly journals A Two-year Randomized Clinical Trial of Chlorhexidine Varnish on Dental Caries in Chinese Preschool Children

2006 ◽  
Vol 85 (6) ◽  
pp. 557-559 ◽  
Author(s):  
M.Q. Du ◽  
B.J. Tai ◽  
H. Jiang ◽  
E.C.M. Lo ◽  
M.W. Fan ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Preschool Children ◽  
Dental Caries ◽  
Test Group ◽  
World Health ◽  
Primary Molars ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Health Organization ◽  
Double Blinded

The objective of this study was to assess the effect of six-monthly professional applications of chlorhexidine varnish on the prevention of dental caries in primary molars in Chinese preschool children. In a double-blinded, randomized, placebo-controlled clinical trial, 334 children aged 4–5 years were randomly divided into two groups. Children in the test group received six-monthly applications of a 40% chlorhexidine varnish, and the control children received a placebo varnish. Caries status of the children was assessed by two calibrated examiners at baseline and after 24 months, according to criteria recommended by the World Health Organization. The two-year mean caries increments in the test and the control group children were 1.0 and 1.6 decayed, missing, or filled molar surfaces (dmfs-molar), respectively, a 37.3% reduction ( t test, p = 0.036). No side-effects were found. It was concluded that six-monthly applications of chlorhexidine varnish were effective in reducing the incidence of dental caries in primary molars.

scholarly journals Health and fertility in World Health Organization group 2 anovulatory women

2012 ◽  
Vol 18 (5) ◽  
pp. 586-599 ◽  
Author(s):  
◽  
D. T. Baird ◽  
A. Balen ◽  
H. F. Escobar-Morreale ◽  
J. L. H. Evers ◽  
...  
Keyword(s):  
World Health Organization ◽  
World Health ◽  
Group 2 ◽  
Health Organization

scholarly journals No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial

2017 ◽  
Vol 102 (5) ◽  
pp. 1642-1651 ◽  
Author(s):  
Thomas Nordstrøm Kjær ◽  
Marie Juul Ornstrup ◽  
Morten Møller Poulsen ◽  
Hans Stødkilde-Jørgensen ◽  
Niels Jessen ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Beneficial Effects ◽  
The Metabolic Syndrome

scholarly journals When to resume bariatric surgery after COVID-19 pandemic?: results of patients’ and surgeons’ survey

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Alicja Dudek ◽  
Michał Wysocki ◽  
Maciej Walędziak ◽  
Jacek Szeliga ◽  
Monika Proczko-Stepaniak ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Body Mass Index ◽  
World Health ◽  
Online Surveys ◽  
The World ◽  
Bariatric Patients ◽  
Group 2 ◽  
Health Organization ◽  
Current Body Mass Index ◽  
Group 1

Abstract Background Coronavirus Disease 2019 is affecting most countries around the world, including Poland. In response, all elective surgeries have been postponed. We asked patients and surgeons when they want bariatric surgery to resume after pandemic. The main aim of the study was to determine patients’ and surgeons’ expectations about when to resume bariatric surgery regarding COVID-19 pandemic state. Methods The study was conducted in two groups: Group 1—bariatric patients; Group 2—bariatric surgeons. Two online surveys were distributed. Results A total of 895 patients, 299 before, 596 after surgery and 32 surgeons took part in survey. All patients and surgeons declared willingness to resume bariatric surgeries after pandemic and responded that they should be resumed immediately the World Health Organization announces end of pandemic (42%). The majority of patients before surgery answered that bariatric procedures should be resumed immediately the number of daily incidents begins to decrease (53%). In the patient group, current body mass index (p < 0.001) and contact with COVID+/quarantined persons (p < 0.001) had impact on the response to resumption of bariatric procedures. Conclusions Patients opted to wait for bariatric surgery until the oncological queue has become shorter. Surgeons presented a readiness to resume both procedures in parallel.

scholarly journals Two Live Attenuated Vaccines against Recent Low–and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets

Vaccines ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 74 ◽  
Author(s):  
Larisa Rudenko ◽  
Irina Kiseleva ◽  
Elena Krutikova ◽  
Ekaterina Stepanova ◽  
Irina Isakova-Sivak ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase I ◽  
Reverse Genetics ◽  
Vaccine Candidate ◽  
Clinical Signs ◽  
Influenza Viruses ◽  
Phase I Clinical Trial ◽  
World Health ◽  
Histological Data ◽  
Health Organization

Influenza H7N9 virus is a potentially pandemic subtype to which most people are immunologically naïve. To be better prepared for the potential occurrence of an H7N9 pandemic, in 2017 the World Health Organization recommended developing candidate vaccine viruses from two new H7N9 viruses, A/Guangdong/17SF003/2016 (A/GD) and A/Hong Kong/125/2017 (A/HK). This report describes the development of live attenuated influenza vaccine (LAIV) candidates against A/GD and A/HK viruses and study of their safety and immunogenicity in the ferret model in order to choose the most promising one for a phase I clinical trial. The A/HK-based vaccine candidate (A/17/HK) was developed by classical reassortment in eggs. The A/GD-based vaccine candidate (A/17/GD) was generated by reverse genetics. Ferrets were vaccinated with two doses of LAIV or phosphate-buffered saline. Both H7N9 LAIVs tested were safe for ferrets, as shown by absence of clinical signs, and by virological and histological data; they were immunogenic after a single vaccination. These results provide a compelling argument for further testing of these vaccines in volunteers. Since the A/HK virus represents the cluster that has caused the majority of human cases, and because the A/HK-based LAIV candidate was developed by classical reassortment, this is the preferred candidate for a phase I clinical trial.

scholarly journals When to Resume Bariatric Surgery after COVID-19 Pandemic? – Results of Patients’ and Surgeons’ Survey.

2020 ◽  
Author(s):  
Aicja Dudek ◽  
Alicja Dudek ◽  
Michał Wysocki ◽  
Maciej Walędziak ◽  
Jacek Szeliga ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Body Mass Index ◽  
World Health ◽  
Online Surveys ◽  
The World ◽  
Bariatric Patients ◽  
Group 2 ◽  
Health Organization ◽  
Current Body Mass Index ◽  
Group 1

Abstract BackgroundCOVID-19 is affecting most countries around the world, including Poland. In response, all elective surgeries have been postponed. We asked patients and surgeons when they want bariatric surgery to resume after pandemic. The main aim of the study was to determine patients’ and surgeons’ expectations about when to resume bariatric surgery regarding COVID-19 pandemic state.MethodsThe study was conducted in two groups: Group 1 – bariatric patients; Group 2 – bariatric surgeons. Two online surveys were distributed.Results A total of 895 patients, 299 before, 596 after surgery and 32 surgeons took part in survey. All patients and surgeons declared willingness to resume bariatric surgeries after pandemic and responded that they should be resumed immediately the World Health Organization announces end of pandemic (42%). The majority of patients before surgery answered that bariatric procedures should be resumed immediately the number of daily incidents begins to decrease (53%). In the patient group, current body mass index (p<0.001) and contact with COVID+/quarantined persons (p<0.001) had impact on the response to resumption of bariatric procedures.ConclusionsPatients opted to wait for bariatric surgery until the oncological queue has become shorter. Surgeons presented a readiness to resume both procedures in parallel.

scholarly journals COVID-19- or Tramadol-induced Seizure: A Differential Diagnosis in Young People

2020 ◽  
Vol 10 (4) ◽  
pp. 32009.1-32009.2
Author(s):  
Solmaz Nekoueifard ◽  
◽  
Mohammad Majidi ◽  
Keyword(s):  
Myocardial Infarction ◽  
Acute Kidney Injury ◽  
Differential Diagnosis ◽  
Acute Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Kidney Injury ◽  
World Health ◽  
The World ◽  
Life Threatening ◽  
Health Organization

Coronavirus disease 2019 (COVID-19) was first declared in December 2019 from Wuhan, China [1, 2]. It then has been reported a pandemic in March 2020 by the World Health Organization [3]. Clinical features of COVID-19 are different from asymptomatic to mild to moderate symptoms, such as fever, headache, myalgia, sore throat, anosmia, cough, fatigue headache, hemoptysis, and dyspnea to the life-threatening complications, including shock, pneumonia, acute respiratory distress syndrome, myocarditis, myocardial infarction, acute kidney injury, multi-organ failure, and even death [1, 2].

scholarly journals Is hydroxychloroquine beneficial for COVID-19 patients?

2020 ◽  
Vol 11 (7) ◽  
Author(s):  
Xing Li ◽  
Ying Wang ◽  
Patrizia Agostinis ◽  
Arnold Rabson ◽  
Gerry Melino ◽  
...  
Keyword(s):  
Public Health ◽  
Severe Acute Respiratory Syndrome ◽  
Emergency Care ◽  
Public Health Emergency ◽  
World Health ◽  
Beneficial Effects ◽  
The World ◽  
Health Organization ◽  
Almost All ◽  
Effective Drugs

Abstract The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world1–3, the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 20204. The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir5, to control the disease and halt the pandemic.

Sign in / Sign up

Export Citation Format

Share Document